Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Idiopathic Pulmonary Fibrosis (Zephyrus II)
NCT04419558Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF), sponsored by FibroGen. Started Sep 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04419558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419558.